Who Paid My Doc
Colette Parker
Neurology with Special Qualifications in Child Neurology Jackson, MS Medical Doctor
NPI 1053357749 CMS profile 93101
2500 N State St, Jackson, MS 39216
General payments
$8,663
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Colette Parker of Jackson, MS is reported in the CMS Open Payments database as having received $8,663 across 99 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 80th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,209 | 25 | |
| 2024 | General | $318 | 9 | |
| 2023 | General | $264 | 9 | |
| 2022 | General | $779 | 14 | |
| 2021 | General | $231 | 5 | |
| 2020 | General | $82 | 4 | |
| 2019 | General | $780 | 33 |
Beside peers
- Colette Parker
- Neurology with Special Qualifications in Child Neurology median
- Middle half of Neurology with Special Qualifications in Child Neurology
- National median
In program year 2025, general payments to Colette Parker were reported at $6,209. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.
Show as a table
| Year | Colette Parker | Neurology with Special Qualifications in Child Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $780 | $262 | $68–$1,313 | $163 |
| 2020 | $82 | $188 | $46–$1,222 | $114 |
| 2021 | $231 | $183 | $45–$1,356 | $132 |
| 2022 | $779 | $229 | $72–$1,177 | $149 |
| 2023 | $264 | $269 | $93–$1,195 | $160 |
| 2024 | $318 | $300 | $98–$1,428 | $164 |
| 2025 | $6,209 | $276 | $87–$1,522 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
146
Drug cost
$140,520
Branded share of claims
35.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Epidiolex Cannabidiol (Cbd) | Brand | 26 | $136,491 | |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | Brand | 15 | $1,287 | |
| Divalproex Sodium | Generic | 23 | $828 | |
| Levocarnitine | Generic | 11 | $550 | |
| Amantadine Amantadine Hcl | Brand | 11 | $433 | |
| Risperidone | Generic | 11 | $308 | |
| Zonisamide | Generic | 12 | $229 | |
| Baclofen | Generic | 13 | $172 | |
| Phenobarbital | Generic | 12 | $161 | |
| Diazepam | Generic | 12 | $60 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
5 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| DAYBUE |
|
$32 | — | — |
| ZTALMY |
|
$30 | — | — |
| Fintepla |
|
$26 | — | — |
| VALTOCO |
|
$24 | — | — |
| GABLOFEN |
|
$23 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
99 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology with Special Qualifications in Child Neurology in Mississippi
John Ingram
Neurology with Special Qualifications in Child Neurology · Jackson, MS
Marcus Lee
Neurology with Special Qualifications in Child Neurology · Ocean Springs, MS
Vettaikorumakankav Vedanarayanan
Neurology with Special Qualifications in Child Neurology · Madison, MS
Ashley Stanley-Copeland
Neurology with Special Qualifications in Child Neurology · Jackson, MS
Lamar Davis
Neurology with Special Qualifications in Child Neurology · Jackson, MS
Ameze Ero
Neurology with Special Qualifications in Child Neurology · Jackson, MS
Related records
Neurology with Special Qualifications in Child Neurology in Mississippi
Practitioners in the same specialty and state, ranked by reported value.
All Neurology with Special Qualifications in Child Neurology
Everyone recorded under this specialty, nationwide.
Doctors in Mississippi
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.